Thrombospondin-1 Inhibits Nitric Oxide Signaling via CD36 by Inhibiting Myristic Acid Uptake*

Received for publication, February 23, 2007, and in revised form, March 28, 2007. Published, JBC Papers in Press, April 5, 2007. DOI 10.1074/jbc.M701638200

Jeff S. Isenberg‡, Yifeng Jia‡, Julia Fukuyama‡, Christopher H. Switzer‡, David A. Wink‡, and David D. Roberts‡1

From the ‡Laboratory of Pathology and §Radiation Biology Branch, Center for Cancer Research, NCI, National Institutes of Health, Bethesda, Maryland 20892

Although CD36 is generally recognized to be an inhibitory signaling receptor for thrombospondin-1 (TSP1), the molecular mechanism for transduction of this signal remains unclear. Based on evidence that myristic acid and TSP1 each modulate endothelial cell nitric oxide signaling in a CD36-dependent manner, we examined the ability of TSP1 to modulate the fatty acid translocase activity of CD36. TSP1 and a CD36 antibody that mimics the activity of TSP1 inhibited myristate uptake. Recombinant TSP1 type 1 repeats were weakly inhibitory, but an anti-angiogenic peptide derived from this domain potently inhibited myristate uptake. This peptide also inhibited membrane translocation of the myristoylated CD36 signaling target Fyn and activation of Src family kinases. Myristate uptake stimulated cGMP synthesis via endothelial nitric-oxide synthase and soluble guanylyl cyclase. CD36 ligands blocked myristate-stimulated cGMP accumulation in proportion to their ability to inhibit myristate uptake. TSP1 also inhibited myristate-stimulated cGMP synthesis by engaging its receptor CD47. Myristate stimulated endothelial and vascular smooth muscle cell adhesion on type I collagen via the NO/cGMP pathway, and CD36 ligands that inhibit myristate uptake blocked this response. Therefore, the fatty acid translocase activity of CD36 elicits pro-angiogenic signaling in vascular cells, and TSP1 inhibits this response by simultaneously inhibiting fatty acid uptake via CD36 and downstream cGMP signaling via CD47.

Pathological angiogenesis or the lack thereof underlies a number of major diseases (1). Proangiogenic signals from vascular endothelial growth factors (VEGF)2 and fibroblast growth factors (FGF1 and FGF2) to induce blood vessel formation are opposed by signals from endogenous angiogenesis inhibitors, including two thrombospondins (TSP1 and TSP2) and proteolytic fragments of several extracellular matrix components (2, 3). Defining the mechanism of action of these inhibitors has been complicated by the finding that vascular cells express multiple receptors for several of these molecules. In the case of TSP1, endothelial cells express at least eight receptors, and some of these elicit pro- rather than anti-angiogenic responses (4, 5). The activities of some TSP1 receptors differ between large vessel and microvascular endothelial cells, and some are regulated by specific contextual signals (4–6).

CD36, a member of the scavenger receptor B family, is a TSP1 receptor that is selectively expressed in microvascular endothelium (7, 8). CD36 was initially reported to recognize CSVTGC sequences in the type 1 repeats of TSP1 (9), but further studies identified higher affinity binding to the adjacent GVQXR sequences in the second and third type 1 repeats (10, 11). CD36 binding was markedly enhanced by epimerization of the first Ile in a peptide from the second type 1 repeat 434GDGVITRIR442, where I (Ile) is the D isomer (11). TSP1, recombinant type 1 repeats of TSP1, and peptide mimetics of its CD36 binding sequences inhibit FGF2-stimulated endothelial cell migration and induce apoptosis in vitro and inhibit FGF2-induced corneal angiogenesis in vivo. The pro-apoptotic signal from CD36 requires activation of the Src family kinase p59-Fyn, signaling through p38, and downstream activation of caspase-3-like proteases (12). c-Jun NH2-terminal kinase-1 is also involved in the anti-motility activity of TSP1 mediated by CD36 (13). Combined with the observation that several Src family kinases co-immunoprecipitate with CD36 (14, 15), these results imply that TSP1 signals through CD36 via a physical coupling to Fyn activation. However, a subsequent study concluded that Src kinases and CD36 mutually associate with lipid rafts but lack any direct binding interaction (16).

We recently identified a new downstream target for the anti-angiogenic activity of TSP1 that involves CD36 (17). Low concentrations of nitric oxide (NO) stimulate angiogenesis through a cGMP-dependent pathway. NO is synthesized in endothelial cells by endothelial nitric-oxide synthase (eNOS), and eNOS in turn is activated by Akt-mediated phosphorylation of eNOS stimulated by VEGF signaling (18). Several studies have provided evidence that NO is an essential mediator of VEGF-stimulated angiogenesis (19, 20). We found that NO-

---

* This research was supported by the Intramural Research Program of the NCI, National Institutes of Health, Center for Cancer Research. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 To whom correspondence should be addressed: National Institutes of Health, Bldg. 10, Room 2A33, 10 Center Dr. MSC1500, Bethesda, MD 20892. Tel.: 301-496-6264; E-mail: droberts@helix.nih.gov.

2 The abbreviations used are: VEGF, vascular endothelial growth factor; cGK, cGMP-dependent protein kinase; EGM, endothelial growth medium (with additives); EBM, endothelial basal medium (without additives); sGC, soluble guanylyl cyclase; FFA, fatty acid free; FGF, fibroblast growth factor; VSMC, vascular smooth muscle cells; HAVSMC, human aortic VSMC; HUVEC, human umbilical vein endothelial cells; L-NAME, N-nitro-L-arginine methyl ester; MetAP2, methionine aminopeptidase-2; ODQ, 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one; Rp-8-cPT-cGMPs, 8-(4-chlorophenylthio)guanosine-3′,5′-cyclic monophosphorothioate, Rp isomer; sGC, soluble guanylyl cyclase; SM-BM, smooth muscle cell basal medium; SSO, sulfosuccinimidyl oleate; TSP1, thrombospondin-1; TSR, TSP1 type 1 repeats; FCS, fetal calf serum; BSA, bovine serum albumin; BisTris, 2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol; PBS, phosphate-buffered saline; Ab, antibody; WT, wild type.
stimulated cGMP signaling in both endothelial and vascular smooth muscle cells is potently inhibited by picomolar concentrations of TSP1, its type 1 repeats, and CD36 antibodies (17, 21). In endothelial cells, TSP1 blocked VEGF-stimulated cGMP synthesis.

Although engaging CD36 is sufficient to inhibit NO signaling as well as VEGF-induced cGMP formation, we subsequently found that CD36 is not necessary for the same activity of intact TSP1 (21, 22). Rather, we found that the TSP1 receptor CD47 is necessary and sufficient for the anti-angiogenic signal elicited by picomolar concentrations of TSP1. However, a weaker inhibitory activity of TSP1, observed at 1–10 nM, was deficient in CD36 null vascular cells (22). Furthermore, synthetic derivatives of CD36-binding peptides, similar to those currently in phase II clinical trials as angiogenesis inhibitors (23, 24), required CD36 for their ability to potently inhibit NO signaling. It is important, therefore, to identify the molecular mechanism by which TSP1, these TSP1 mimetics, and CD36 influence NO signaling in endothelial and vascular smooth muscle cells.

CD36 also has fatty acid translocase activity (for review, see Ref. 25). Myristic acid was recently shown in a CD36- and AMP kinase-dependent manner to activate eNOS (26). This observation prompted us to ask whether TSP1 and its CD36 binding sequences might modulate NO signaling through antagonizing fatty acid uptake via CD36 and thereby inhibit endogenous NO synthesis. We report here that TSP1 inhibits both signaling and functional responses of endothelial cells elicited by myristate. Although myristate uptake into some cells may not require CD36 and the activity of myristate to activate eNOS was inferred on this basis to be independent of uptake (26), we now show that TSP1 peptide mimetics are potent inhibitors of myristate uptake into endothelial cells. Consistent with its known effect on eNOS activity (26), myristate treatment of endothelial cells elicits similar functional and biochemical responses as exposure to an NO donor, and these responses are effectively blocked by TSP1 peptide mimetics and other CD36 ligands that inhibit its translocase activity. We further show that membrane targeting of the known CD36 signaling target Fyn is stimulated by myristate and inhibited by antagonist ligands.

**EXPERIMENTAL PROCEDURES**

**Cells and Reagents**—HUVEC and HAVSMC (Cambrex, Walkersville, MD) were maintained in either endothelial cell growth medium (EGM, Cambrex) with 2% FCS or vascular smooth muscle growth medium (SMGM, Cambrex) with 2% FCS in 5% CO2 at 37 °C. Cells were utilized at passages 4–8. Smooth muscle growth medium (SMGM, Cambrex) with 2% FCS or vascular smooth muscle growth medium as described (22). Cells were used between passages 2 through 8. TSP1 was prepared from human platelets obtained from the Blood Bank of the Clinical Center of the NIH as previously described (27). The recombinant fragment of the type 1 repeat domain of TSP1 (3TSR) was graciously provided by Dr. Jack Lawler (Harvard University). TSP1-derived peptides 488VTAGGGVQKRSRL900 (p906) and 434GDGVTRIR442 (where I (Ile) is the D isomer; p907) were synthesized by Peptides International (Louisville, KY). The underlined residues indicate modifications from the natural TSP1 sequence. Additional CD36 (488VTAGGGVQKRSRL900, p245)- and CD47-binding peptides (1102FIRVVMYEGKK1112, p7N3) derived from TSP1 were available from previous studies. The CD36 antagonist antibody clone FA6–152 was obtained from Immuno- tech (Beckman Coulter, Fullerton, CA). The CD36 agonist antibody clone SMΦ was purchased from Chemicon International (Temecula, CA). 1H-[1,2,4]oxadiazole[4,3-a]quinoxalin-1-one (ODQ), N-nitro-L-arginine methyl ester (L-NAME), fatty acid free bovine serum albumin (FAF BSA), myristic acid, and oleic acid were obtained from Sigma-Aldrich. [3H]Myristic acid was also obtained from Sigma. Type I bovine dermal collagen was obtained from Inamed Biomaterials (Santa Barbara, CA). Human vitronectin was obtained from Sigma. Fibronectin was purified from human plasma (28), and a 33-kDa recombinant fragment containing the αsβ integrin binding site of fibronectin (FN-33) was provided by Dr. Tikva Vogel (29). cGMP measurement was performed with an immunoassay kit obtained from Amersham Biosciences. The CGK inhibitor Rp-8-pCPT-cGMP was obtained from Calbiochem (EMD Biosciences, San Diego, CA). A CD36 morpholinophosphorodiamidate oligonucleotide targeting the human protein and having the sequence GCCCACAGTCTCGGTCAAGCCCAT was purchased from Gene Tools (Philmoth, OR) along with a 5-base mismatched control morpholino (GCgCAGGTTCGCT-TCAcCcAG).**

**Immunoprecipitation of CD36**—HUVEC and HAVSMC were cultured in standard growth medium on 10-cm culture plates to a density of 90% surface saturation and harvested with EDTA. Cell pellets were washed 3× with cold Dulbecco’s PBS, and cells were counted. Equal cell numbers were incubated with Sulfo-NHS-LC-Biotin (Pierce) (1 mg/100 µl molecular grade water) for 30 min at room temperature and washed again 3× in cold Dulbecco’s PBS. The cell pellet was resuspended in radioimmune precipitation assay buffer containing 1 mM phenylmethylsulfonyl fluoride, incubated for 20 min at 4 °C, and centrifuged at 13,000 rpm for 15 min. The supernatant was incubated with protein G-ferrous beads (Dynabeads, Dynal Biotech, Olso, Norway) and a monoclonal CD36 antibody, clone FA6–152 (ImmunoJech, Beckman Coulter), overnight at 4 °C. Beads were washed with cold radioimmune precipitation assay buffer 3× and then boiled in sample buffer at 95 °C for 10 min. Protein levels of samples were then determined by MicroBCA assay (Pierce), and equal amounts of protein were loaded and electrophoresed in 4–12% BisTris NuPAGE gels and transferred to polyvinylidene difluoride membranes. Membranes were blocked with PBS and 3% BSA for 1 h, incubated with streptavidin (1:20,000) (Sigma) for 1 h, and then developed with Visualizer Spray & Glow (Upstate, lake Placid, NY).

**CD36 Knockdown Experiments**—HUVEC were treated as per the manufacturer’s recommendations in growth medium with the indicated concentrations of CD36 antisense or mismatched control morpholino for 48 h before analysis.

**Sulfosuccinimidyl Oleate (SSO) Synthesis**—SSO was synthesized as described (30). Briefly, 0.25 mmol each of oleic acid and N-hydroxysulfosuccinimide and 0.275 mmol of dicyclohexylcarbodiimide were reacted in 0.5 ml anhydrous N,N-diethylformamide overnight at room temperature. The dicyclo-
hexylurea was crystallized out, and the solution was filtered and chilled. The product was then precipitated out of solution by the addition of cold ethyl acetate and dried under vacuum over phosphorous pentoxide. Working solutions of SSO were prepared immediately before each use.

**Cell Adhesion**—Cell adhesion was carried out in 96-well plates (Nunc, Denmark). After precoating wells with type I collagen (3 μg/ml), vitronectin (1 or 2 μg/ml), fibronectin (3 μg/ml), or FN-33 (1.5 or 3 μg/ml), HUVEC, HAVSMC, or CD47 null VSMC were plated at a density of 1 × 10^4 cells/well in EBM or SM-BM containing 0.1% FAF BSA and treatment agents and incubated in 5% CO₂ for 1 h. Wells were washed with PBS, and the cells were fixed with 1% glutaraldehyde for 10 min, washed, and stained with 1% crystal violet for 20 min. Excess stain was rinsed away, the cells were extracted with 10% acetic acid, and the plates were read at 570 nm.

**Intracellular cGMP Measurement**—HUVEC or HAVSMC were plated in 96-well culture plates at a density of 5 × 10^3 cells/well in EGM or smooth muscle cell growth medium plus 2% FCS. After a 24-h incubation, cells were weaned to EBM or SM-BM plus 1% FCS and incubated an additional 24 h. Cells were then treated in EBM or smooth muscle cell growth medium plus 0.1% FAF BSA with myristic acid at the indicated concentrations. After a 5-min incubation, cells were lysed, and intracellular cGMP was determined by immunoassay enzyme-linked immunosorbent assay as per the manufacturer’s instructions.

[^3H]Myristic Acid Uptake—The[^3H]myristic acid uptake assays were performed using 80–90% confluent HUVEC cells (5 × 10^3 cells/well) in 24-well culture plates (Nunc, Denmark). Trace amounts of[^3H]myristic acid (5 μCi/ml, 0.9 μM) mixed with 9.1 μM nonradioactive myristic acid were dissolved in a FAF BSA solution at a myristic acid/BSA molar ratio of 1:2. Cells were incubated in medium with treatment agents for the indicated time intervals at 37 °C. The uptake was stopped by removal of the solution followed by the addition of chilled 0.9% NaCl with 0.5% BSA. The stop solution was discharged, and the cells were washed again with stop solution. Cells were lysed by adding 0.2 M NaOH (200 μl/well) and incubating for 2 h at 37 °C. On completion of solubilization, 0.2 M HCl in 1.5 M Tris-HCl (200 μl) was added to each well. Radioactivity was determined in 10 ml of Ecoscint A (National Diagnostics, Atlanta, GA) using a 1900CA liquid scintillation counter (Packard Instrument Co.).

**Detection of Fyn Translocation**—HUVEC were plated on 100-mm plates in 2% FCS EGM and grown to 80% confluence. Cells were weaned over 24 h to EBM containing 1% FCS. After weaning, cells were pretreated in EBM containing 0.1% FAF BSA with and without peptide p907 (10 μM) for 15 min, then incubated for 1 h in the presence of myristate (10 μM). After treatment cells were rinsed, scraped in ice-cold STE (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, and 1 mM EDTA, 1× protease inhibitor mixture tablet (Roche)), and centrifuged at 1500 rpm for 5 min. The cell pellet was resuspended into 200 μl of hypotonic buffer (10 mM Tris-HCl, pH 7.2, 0.2 mM MgCl₂, 100 mM Na₃VO₄, and 1× protease inhibitor mixture tablet) and homogenized with 30 strokes in a 1.5-ml Dounce homogenizer. To ensure a complete cell lysis, cells were freeze-thawed twice at −80 °C. The homogenate volume was adjusted to a final concentration of 250 mM sucrose and 1 mM EDTA and centrifuged for 45 min at 100,000 × g. The S100 fraction was collected into 4× SDS sample buffer, and P100 was collected into 1× SDS sample buffer. Samples were separated by electrophoresis and blotted onto polyvinylidene difluoride membranes. Membranes were probed with anti-Fyn Ab (BD Transduction Laboratories, catalog no. 610163) or eNOS (BD Transduction Laboratories) at 4 °C overnight and followed by 1 h of incubation at room temperature with goat-anti-mouse secondary antibody conjugated with horseradish peroxidase (Jackson ImmunoResearch). After washing with Tris-buffered saline, the bound antibodies were detected by ECL (Pierce). The membrane was then reprobed with anti-actin antibody (Sigma) for loading control.

**Detection of Src Family Kinase Phosphorylation**—HUVEC were starved overnight in EBM containing 1% FCS, rinsed, and treated with the indicated reagents in EBM with 0.1% FAF BSA. Cells were treated with p907 (10 μM) for 15 min before the addition of VEGF or myristate. VEGF was added at 20 ng/ml for 5 min and myristate (10 μM) for 15 min. Cells were then rinsed with PBS and collected in SDS sample buffer, separated by electrophoresis, and blotted onto polyvinylidene difluoride membranes. Membranes were probed with anti-Src-Tyr⁵¹⁶ phosphorylated Ab (Cell Signaling) or anti-Src Ab (Cell Signaling). Membranes were reprobed with anti-actin antibody for loading control.

**Statistics**—All assays were repeated at least in triplicate and are presented as the mean ± S.D. with significance being determined by Student’s t test for a p > 0.05.

**RESULTS**

**Inhibition of Myristic Acid Uptake by TSP1, CD36-binding Peptides, and SSO**—To assess the ability of TSP1 to modulate the fatty acid translocase activity of CD36, HUVEC at ~80% confluence were transferred into serum-free medium and treated with[^3H]myristic acid (10 μM) precomplexed with 0.1% FAF BSA. Myristic acid uptake under these conditions was time-dependent, and 5 min was used for subsequent experiments (Fig. 1A). Preincubation of HUVEC with exogenous TSP1 before incubating for 5 min with[^3H]myristic acid at 37 °C dose dependently inhibited up to 60% of myristic acid uptake (Fig. 1B). Recombinant type 1 repeats of TSP1 (3TSR) were less effective, reaching significance only at 483 nM, whereas the CD47 binding C-terminal domain of TSP1 did not significantly inhibit myristic acid uptake (Fig. 1B). This inhibitory activity was specific for TSP1 in that equimolar concentrations of laminin-1 and vitronectin were inactive. Myristate uptake into human aortic VSMC was also inhibited in a dose-dependent manner by TSP1 (Fig. 1C).

Myristate uptake in HUVEC was not significantly inhibited by a reported CD36-binding peptide from the third type 1 repeat of TSP1 (p245, VTCGGGVQKRSRL) or a derivative of the same peptide in which the native Cys was substituted with Ala to prevent dimerization (p906, VTAGGGVQKRSRL, Fig. 1D). However, uptake of myristic acid was strongly inhibited in the presence of ≥0.1 μM CD36-binding peptide GDGVITRIR derived from the second type 1 repeat of TSP1 by epimerization.
of Ile^{38} to the d isomer (11) (p907, Fig. 1D). As a further control, a CD47-binding peptide derived from the C-terminal domain of TSP1 also failed to inhibit myristate uptake (Fig. 1E).

To further examine the role of CD36 in myristate uptake into HUVEC, we tested the widely used antagonist of CD36 fatty acid translocase activity SSO (30, 31). SSO dose-dependently inhibited up to 80% of [\( ^{3}H \)]myristic acid uptake in HUVEC, but its IC_{50} was ~100-fold higher than for the TSP1-based CD36 ligand p907 (Fig. 1F).

We confirmed CD36 expression in both vascular cell types by Western blotting (Fig. 2A). Because expression was substantially higher in HAVSMC than in HUVEC, we used the former cells to confirm the role of CD36 in myristate uptake by knocking down CD36 expression using a translation blocking antisense morpholino oligonucleotide. Western blotting confirmed efficient suppression of CD36 protein expression at 10 \( \mu M \) morpholino (Fig. 2B), and this concentration decreased myristate uptake by ~50% (Fig. 2C). Activity of the antisense morpholino was specific in that a 5-base mismatched morpholino did not inhibit myristate uptake. The incomplete inhibition of myristate uptake by CD36 knock down is consistent with previous evidence for both CD36-dependent and CD36-independent uptake of free fatty acids into cells (32–34).

Myristic Acid Uptake Is Blocked by CD36 “Agonist” but Not by “Antagonist” Antibodies—The ability of different CD36 antibodies to mimic or block the anti-angiogenic activities of TSP1 and its derived peptides was presented as evidence that CD36 mediated this activity of TSP1 (10). CD36 antibody SM9021, which is defined as an agonist because it replicates the activity of TSP1 as an angiogenesis inhibitor (10), potently inhibited myristic acid uptake into HUVEC at 10 ng/ml (Fig. 2D). In contrast, CD36 antibody FA6–152, which antagonized TSP1 in the same angiogenesis assays but did not itself inhibit angiogenic responses (10, 12, 13), had no effect upon myristic acid uptake into endothelial cells even at 10 \( \mu g/ml \) (Fig. 2D).

Thus, the CD36-dependent anti-angiogenic activities of TSP1, a peptide mimic of its type 1 repeats, and two CD36 antibodies correlate with their ability to inhibit the fatty acid translocase activity of CD36. Because CD36 has been implicated in the ability of exogenous myristic acid to activate eNOS (26) and in the ability of TSP1 to inhibit NO signaling in endothelial and VSMC (17, 21), we considered that both vascular cell responses may be mediated by myristic acid transport via CD36, which provides a required precursor for myristoylation of more than 100 proteins, including several key signaling molecules (35).

One myristoylated protein that was shown previously to be a target of CD36 signaling in endothelial cells is the Src kinase Fyn (12). Myristoylation of Fyn is required for subsequent palmitoylation, methylation, membrane translocation, and some functional responses mediated by Fyn (36). Medium containing serum provided adequate myristic acid to maintain full Fyn association with the membrane (P100) fraction in HUVEC (Fig. 3A). In serum-free medium, however, Fyn was localized
primarily to the cytosolic (S100) fraction (Fig. 3A and results not shown). Under these conditions, translocation of Fyn from the cytosol to the cell membrane in HUVEC was rapidly stimulated by the addition of 10 μM myristate to the medium complexed with FAF BSA. The myristate-stimulated translocation, however, was prevented in the presence of p907 (Fig. 3A).

FIGURE 2. Morpholino suppression of CD36 and a CD36 blocking antibody decrease myristate uptake into vascular cells. A, HUVEC and human aortic VSMC were cultured in standard growth medium, surface labeled with biotin, lysed, and immunoprecipitated using a monoclonal antibody to CD36. Equal amounts of protein were electrophoresed, transferred to membranes, and detected using streptavidin-peroxidase and chemiluminescent detection. B, HAVSMC grown under standard growth conditions and treated for 48 h with a CD36 morpholino (0–10 μM) and CD36 expression was determined. C, HUVEC (5 × 10⁴ cells/well) were plated in 24-well culture plates in EGM plus 2% FCS, treated with an antisense CD36 or control morpholino, and weaned over 48 h to EBM plus 0.1% BSA. Cells were then treated with [³H]myristate for 5 min, and uptake into cells was determined. D, HUVEC were plated in 24-well culture plates in EGM plus 2% FCS and weaned over 48 h to EBM plus 0.1% FAF BSA. Cells were then treated with an agonist CD36 monoclonal antibody clone SMΦ or antagonist antibody clone FA6-152 at the indicated concentrations and incubated with [³H]myristate complexed to FAF BSA for 5 min, and uptake into cells was determined as described.

FIGURE 3. Inhibition of CD36-mediated myristate uptake into endothelial cells by a TSP1-based peptide blocks rapid membrane translocation of Fyn and activation of Src kinases. A, HUVEC were plated into 100-mm plates and cultured in 2% FCS EGM to 80% confluence and serum-starved over 24 h. The next day cells were treated in EBM containing 0.1% FAF BSA with or without peptide-907 (10 μM) for 15 min with and without myristate (10 μM) or EBM-1% FCS for 60 min. Cells were lysed, and the homogenate was separated by ultracentrifugation into membrane (P100) and cytosol fractions (S100). Proteins were separated by electrophoresis and analyzed by Western blotting using Fyn and actin antibodies. B, HUVEC were starved overnight in 1% FBS-EBM, rinsed, and treated with the indicated reagents in EBM with 0.1% FAP BSA; that is, p907 at 10 μM for 15 min before the addition of VEGF or Myr. VEGF was added at 20 ng/ml for 5 min and myristate at 10 μM for 15 min. Cells were then rinsed with PBS and collected in SDS sample buffer. Westerns blots were probed with anti-Src-Tyr416 (Src-Y⁴¹⁶) phosphorylated (Cell Signaling) or anti-Src (Cell Signaling). Membranes were reprobed with anti-actin antibody for loading control. Results presented are representative of three independent experiments.
This translocation appears to increase Fyn activation because treatment of HUVEC in FAF BSA with myristate increased Tyr416 phosphorylation to a similar extent as the known Fyn activator VEGF (Fig. 3B) (37, 38). Furthermore, the addition of p907 strongly inhibited Tyr416 phosphorylation induced by myristate and to a lesser extent Tyr416 phosphorylation induced by VEGF (Fig. 3B). It should be noted that the Tyr416 antibody used is pan-Src-reactive, and two phosphorylated bands were apparent in most experiments, so other members of the Src family may also be activated in response to exogenous myristate in a CD36-dependent manner.

We also considered whether the reported CD36-dependent positive effect of exogenous myristate on eNOS activity (26) could result from regulating membrane translocation of this myristoylated enzyme (39, 40). In contrast to Fyn, almost all eNOS was associated with the membrane fraction in cells starved overnight regardless of treatment (Fig. 3A). The small amount of eNOS in the cytoplasmic fraction could be decreased by adding serum or myristate, but adding p907 only minimally increased the fraction of soluble eNOS. Therefore, the effects of myristate and p907 on NOS activity (see below) probably cannot be explained by altered translocation of eNOS within the time scale of these experiments. However, the relative insensitivity of eNOS to myristate starvation for this time period is consistent with its slow turnover rate (41).

Myristic Acid Increases cGMP Levels in Endothelial Cells via CD36 and Is NOS-dependent—If myristate levels are rate-limiting for the targeting or activity of signaling molecules that regulate the NO/cGMP pathway, such signaling should be stimulated by providing exogenous myristic acid, and agents that block myristic acid uptake through CD36 should inhibit this signaling. The low levels of NO produced by eNOS cannot be directly measured, but soluble guanylyl cyclase (sGC) activation is a sensitive indicator of endogenous NO and can be assessed by intracellular cGMP formation (42). Treatment with myristic acid increased intracellular cGMP in HUVEC measured at 5 min in a dose-dependent manner, with a maximum response occurring at a dose of 10 μM (Fig. 4A). Time course studies confirmed that the stimulatory effect of 10 μM myristic acid was rapid and transient, with maximal accumulation occurring at 5–10 min. (Fig. 4B and results not shown). Exogenous TSP1 at a concentration adequate to inhibit NO-stimulated cGMP accumulation (17) also inhibited myristic acid stimulated cGMP in HUVEC (Fig. 4C).
The myristate-stimulated accumulation of cGMP in HUVEC requires CD36 because pretreatment with the CD36 antisense morpholino but not a control morpholino decreased intracellular cGMP to basal levels (Fig. 4D). Similar results were obtained after CD36 knockdown in HAVSMC (Fig. 4E). To further confirm the CD36 translocase dependence for myristic acid stimulated cGMP accumulation, we used the inhibitor SSO (Fig. 4F). No stimulation of cGMP accumulation by myristic acid was seen after preincubation of HUVEC with this translocase inhibitor.

Consistent with the CD36-dependent activation of eNOS by myristate (26), pretreatment of endothelial cells with L-NAME (500 μM) completely abrogated myristic acid-stimulated cGMP (Fig. 4G), indicating that NOS activity is required for this cGMP response.

The potent CD36-binding peptide p907 at 10 μM completely inhibited myristic acid-stimulated intracellular cGMP (Fig. 5A), but the control p906 was inactive (Fig. 5B). These results are consistent with the differential activities of these two peptides to block the fatty acid transport activity of CD36 (Fig. 1).

Myristate Stimulates Endothelial Cell Adhesion via CD36—We previously reported that NO/cGMP signaling stimulates endothelial cell adhesion on type I collagen (17). Similarly, HUVEC cell adhesion on a type I collagen substrate was stimulated in a dose-dependent manner by myristic acid and was optimal at 10 μM (Fig. 6A), consistent with the optimal dose for cGMP accumulation (Fig. 4A). The effect of myristate on cell adhesion was specific in that similar concentrations of oleic acid were inactive, although oleic acid above 100 μM moderately increased cell attachment (Fig. 6A).

To determine whether the effect of myristate on adhesion is substrate-dependent, we examined several proteins that mediate adhesion via different integrins (Fig. 6B). Myristate (10 μM) significantly enhanced HUVEC adhesion on fibronectin, a recombinant fragment of fibronectin containing its RGD sequence, and the αβ1 ligand vitronectin as well as on the α1β1/α2β1 substrate type I collagen. Therefore, stimulation of endothelial cell adhesion by myristate can be mediated by several integrins. As shown below, this property also generalizes to VSMC.

If myristic acid uptake via CD36 is responsible for the increase in HUVEC adhesion, then blocking the fatty acid translocase activity of CD36 using SSO (30, 31) should also inhibit this response. Myristic acid-stimulated HUVEC adhesion to type I collagen was inhibited in a dose-dependent manner by SSO (Fig. 6C). Similarly, myristate-stimulated adhesion was abolished in cells pretreated with the CD36 antisense morpholino but not in cells pretreated with the mismatched control (Fig. 6D).

Myristate Stimulates Adhesion via the eNOS/sGC/cGK Pathway—Stimulation of HUVEC adhesion by myristate required NOS activity based on inhibition of myristic acid-stimulated cell adhesion by L-NAME (Fig. 6E). The primary target the low NO flux produced by eNOS is the regulatory heme in sGC. The role of sGC was confirmed by abrogation of myristate-stimulated cell adhesion in the presence of 10 μM ODQ (Fig. 6F). cGMP produced by sGC in turn regulates downstream signaling by activating cGK or cGMP-dependent ion
TSP1 and Other Inhibitory CD36 Ligands Block Myristate-stimulated Cell Adhesion—Exogenous TSP1 dose-dependently inhibited myristate-stimulated HUVEC adhesion on type I collagen (Fig. 7A). TSP1 at 2.2 nM similarly inhibited HAVSMC adhesion on type I collagen and on the αβ3 binding domain of fibronectin but did not achieve significance in three independent experiments for myristate-stimulated adhesion on the αβ3 substrate vitronectin (Fig. 7B and results not shown). Although TSP1 is a ligand for some of these integrins (43, 44), the binding affinities are too low for direct competition by 2.2 nM TSP1 to account for the observed inhibition.

The CD36 binding recombinant TSP1 type 1 repeats (3TSR) inhibited HUVEC adhesion to collagen driven by myristic acid at relatively high doses (Fig. 7C), consistent with its weak activity to inhibit myristic acid uptake (Fig. 1B), but myristate-stimulated adhesion was more sensitive to inhibition by the CD36-binding p907 (Fig. 7D). Consistent with their inability to significantly inhibit myristic acid uptake at achievable concentrations (Fig. 1C), two CD36-binding peptides lacking the N-Ile inversion, p906 and p245 (10, 45), did not inhibit cell adhesion (Fig. 7, D and E). The activities of CD36 antibodies SMΦ and FA6 152 also paralleled their activity to inhibit myristic acid uptake (Fig. 2D). Ligation with the agonist CD36 antibody SMΦ dose-dependently inhibited myristic acid-stimulated HUVEC adhesion (Fig. 7F), but the antagonist CD36 antibody FA6 152 did not (Fig. 7G).

CD47 Ligation Indirectly Inhibits Myristate Signaling via CD36—Although the CD47-binding peptide 7N3 did not inhibit myristate uptake (Fig. 1E), it did inhibit myristate-stimulated cell adhesion (Fig. 8A). This could be explained by the ability of CD47 signaling to inhibit NO signaling in vascular cells at the level of sGC (22). In this case some of the inhibition of myristate signaling by TSP1 seen in Fig. 7A could also be indirect and mediated by TSP1 binding to CD47. To test this hypothesis, we first compared the effect of myristate on adhesion of VSMC isolated from WT and CD47 null mice (Fig. 8B). Stimulation of adhesion by myristate was unaffected in a CD47 null background, indicating that CD47 is not necessary for signaling induced by myristate.

As seen for HUVEC, TSP1 (at a dose sufficient to elicit CD47 signaling but not sufficient to directly inhibit myristate uptake via CD36) significantly inhibited adhesion on collagen stimulated by myristate of murine WT but not CD47 null VSMC (Fig. 8C). Therefore, TSP1 via CD47 can indirectly inhibit myristate signaling at the level of sGC.

DISCUSSION

Our data reveal that anti-angiogenic signaling initiated by the interaction of TSP1 and related ligands with CD36 results at least in part from inhibition of its fatty acid translocate activity. Those CD36 ligands that exhibit anti-angiogenic activity inhibit myristate uptake and myristate-dependent NO signaling and downstream cGMP-mediated effects on endothelial cell adhesion (Fig. 9). TSP1 is less potent for inhibiting fatty acid uptake than for inhibiting cGMP signaling via CD47, but this is consistent with the differential responses of murine CD36 null and wild type vascular cells to TSP1 (22). CD47-dependent anti-angiogenic signaling in the context of NO stimulation requires only picomolar concentrations of TSP1. Engaging CD47 does not inhibit myristate uptake but can inhibit myristate signaling downstream of NOS. An anti-angiogenic peptide derived from the CD36 binding type 1 repeats of TSP1, however, is a potent antagonist of fatty acid transport via CD36. This peptide inhibits NO/cGMP/cGK signaling in a NOS-dependent manner and so acts upstream of sGC, which is the major apparent target of CD47-mediated inhibition by
Thrombospondin-1 Inhibits Myristate Uptake via CD36

Native TSP1 (22). Therefore, TSP1 can inhibit two different steps in NO signaling by engaging CD36 versus CD47 on endothelial cells.

Our data suggest an alternate mechanism for the recently described connection between endogenous nitric oxide production and CD36 (26). Zhu and Smart (26) inferred that activation of NOS is mediated by binding of myristic acid and, to a lesser extent, palmitic acid to CD36 without internalization. We now show that agents that inhibit myristate uptake via CD36 prevent NOS-dependent cGMP synthesis. Therefore, uptake of myristate is probably involved in the previously reported NOS activation by this fatty acid. These new results also suggest a mechanistic basis for our previous observations that CD36 ligation modulates several NO-stimulated vascular cell responses (17, 21). In support of this hypothesis, we found that basal HUVEC adhesion to collagen in growth medium containing only FAF BSA is significantly increased upon the addition of myristate. Involvement of NO signaling in stimulation of endothelial cell adhesion by myristate was confirmed by its inhibition in the presence of the nonselective NOS inhibitor l-NAME, the sGC inhibitor ODQ, and the cGK inhibitor Rp-8-pCPT-cGMPS. Taken together these results suggest that the stimulatory effects of myristate on endothelial cell adhesion to type I collagen requires the generation of endogenous NO, which in turn activates sGC and leads to cGK activation via cGMP (Fig. 9).

In addition to regulating NO signaling, myristic acid modifies the function of a number of proteins via N-myristoylation (35), and exogenous myristate has been documented to be efficiently utilized for protein acylation by other cell types (46). One myristoylated protein that was previously implicated in TSP signaling via CD36 is Fyn (12). Although Fyn is necessary for induction of apoptosis and inhibition of corneal angiogenesis by TSP1 (12), other investigators have concluded that Fyn mediates proangiogenic signaling. Fyn is not required for the vascular permeability activity of VEGF (47) but is required for stimulation of mitogenesis and tube formation by VEGF (48). Fyn also contributes to endothelial tube formation and migration stimulated by FGF2 and angiopoietin-2 (49, 50). Conversely, the angiogenesis inhibitor pigment epithelium-derived growth factor specifically down-regulated FGF2-stimulated Fyn activity via Fes (50).

We now show that the positive effects of myristate on endothelial cell signaling and function are associated with increased membrane translocation of Fyn and functional activation of Src family kinases as assessed by Tyr416 phosphorylation. The rapid increase in Fyn translocation after the addition of exogenous myristate that we observed is consistent with the previously reported rapid translocation of this Src kinase after myristoylation (51). Src localization and activation may also be regulated via CD36-mediated myristate uptake because, unlike Fyn, Src is exclusively tethered to membrane via myristoylation (52).

Fyn and other Src family kinases are known to co-precipitate with CD36 in lysates from platelets and endothelial cells (14, 15), but given their mutual association with lipid raft microdomains, this is not proof of their direct interaction. Indeed, a more detailed examination failed to detect direct interaction of Fyn with CD36 (16). Our results show that independent of any potential physical coupling, the fatty acid translocase activity of CD36 can modulate Fyn function by altering its cellular localization and functional activation. Therefore, regulation of Fyn by CD36 probably does not require any physical interaction.

It was surprising that exogenous myristic acid would be required for protein myristoylation given that myristic acid is an abundant component of cellular phospholipids. Presumably,
the free fatty acid pool must be limiting for synthesis of myristoyl-CoA in HUVEC deprived of serum. Additional studies are required to determine whether CD36 globally limits protein myristoylation or acts specifically to regulate trafficking of certain targets such as Fyn. We previously found that TSP1 also inhibits signaling downstream of cGMP (17). Inhibiting myristoylation was previously shown to prevent membrane localization of cGMP-dependent protein kinase II (53). This, therefore, is a potential target for the latter activity of TSP1.

The results of Zhu (26) and our results showing L-NAME inhibition of myristate-induced cGMP signaling indicate that exposure of serum-deprived HUVEC to exogenous myristate rapidly activates eNOS. This could occur by regulation of eNOS myristoylation, which is essential for its membrane localization and function (39, 40, 54). However, the efficient cotranslational myristoylation of eNOS coupled with further palmitoylation may make this target less sensitive to limiting the myristic acid pool (41). Furthermore, the ~20-h half-life of eNOS may preclude detecting a significant shift in distribution of eNOS within the 1-h period of our assay. Because the activity of eNOS is regulated by exogenous myristate within this time frame, translocation of other myristoylated proteins that control eNOS activation, such as the phosphatase PP2B and certain myristoylated peptides (55–57), should be considered. Future studies will examine which myristoylated proteins are responsive to CD36-mediated myristate uptake within the time frame of eNOS activation.

Our observations that CD36 limits myristate uptake and the myristate/CD36-dependent translocation of at least one important signaling protein suggest a common basis for the activities of CD36- and methionine aminopeptidase (MetAP2)-
targeted drugs as angiogenesis inhibitors (Fig. 9). MetAP2 inhibitors such as fumagillin, ovalicin, and TNP-470 prevent cleavage of the NH₂-terminal Met from proteins destined to be myristoylated (58). CD36 transports myristic acid that can be activated by acyl-CoA synthetases to become the substrate for N-myristoyl transferases. Although myristic acid is abundant in membrane phospholipids, our data and that of Zhu and Smart (26) indicate that the availability of free myristic acid is limiting for regulation of eNOS in serum-starved endothelial cells.

This common mechanism is relevant to development of therapeutic angiogenesis inhibitors. Irreversible MetAP2 inhibitors such as TNP470 have toxic side effects that have prompted efforts to develop reversible inhibitors of MetAP2 (59). Our data suggests that the CD36-directed drug ABT-510 may show better efficacy by reversibly blocking access to the myristoyl-CoA needed for tethering Fyn and other signaling proteins to membranes subsequent to MetAP2 cleavage of the terminal Met.

TNP-470 shares with ABT-510 the property of synergizing with radiation to inhibit tumor angiogenesis (60–62). Similar synergism with cytotoxic agents was also noted for TNP-470 and ABT-510 (63, 64). The convergent effects of these two drugs on protein myristoylation may explain these similarities. Furthermore, the myristoylation pathway may play a more general role in tumor growth independent of angiogenesis. N-Myristoyl transferases have been considered as potential targets for anti-neoplastic drugs (65), and MetAP2 is elevated in colon carcinoma (66). Therefore, drugs that target CD36, as well as ABT-510, may also have anti-tumor activities through inhibiting myristate uptake that are independent of angiogenesis.

Acknowledgments—We thank Drs. Jack Lawler and Bill Frazier for providing reagents.

REFERENCES
1. Carmeliet, P. (2005) Nature 438, 932–936
2. Lawler, J., and Detmar, M. (2004) J. Biol. Chem. 279, 2885–2900
3. Calzada, M. J., Zhou, L., Sipes, J. M., Zhang, J., Krutzsch, H. C., Iruela-Arispe, M. L., Annis, D. S., Mosher, D. F., and Roberts, D. D. (2004) Circ. Res. 94, 462–470
4. Chandrasekaran, L., He, C. Z., Al-Barazi, H., Krutzsch, H. C., Iruela-Arispe, M. L., and Roberts, D. D. (2000) Mol. Cell Biol. 20, 6198–6207
5. Asch, A. S., Silbiger, S., Heimer, E., and Nachman, R. L. (1992) J. Clin. Investig. 89, 551–559
6. Liang, X., Lu, Y., Wilkes, M., Neubert, T. A., and Resh, M. D. (2004) J. Biol. Chem. 279, 17665–17668
7. Kerkhoff, C., Sorg, C., Tandon, N. N., and Nacken, W. (2001) Biochemistry 40, 241–248
8. McCormick, C. J., Craig, A., Roberts, D., Newbold, C. L., and Berendt, A. R. (1997) J. Clin. Investig. 100, 2521–2529
9. Asch, A. S., Silbiger, S., Heimer, E., and Nachman, R. L. (1992) Biochem. Biophys. Res. Commun. 182, 1208–1217
10. Dawson, D. W., Pearce, S. F., Zhong, R., Silverstein, R. L., Frazier, W. A., and Bouck, N. P. (1997) J. Cell Biol. 138, 707–717
11. Dawson, D. W., Volpert, O. V., Pearce, S. F., Schneider, A. J., Silverstein, R. L., Henkin, J., and Bouck, N. P. (1999) Mol. Pharmacol. 55, 332–338
12. Jimenez, B., Volpert, O. V., Crawford, S. E., Febbraio, M., Silverstein, R. L., and Bouck, N. (2000) Nat. Med. 6, 41–48
13. Jimenez, B., Volpert, O. V., Reiher, F., Chang, L., Munoz, A., Karin, M., and Bouck, N. (2001) Oncogene 20, 3443–3448
14. Huang, M. M., Bolen, J. B., Barnwell, J. W., Shattil, S. J., and Brugge, J. S. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 7844–7848
15. Bull, H. A., Brickell, P. M., and Dowd, P. M. (1994) FEBS Lett. 351, 41–44
16. Thorne, R. F., Law, E. G., Elth, C. A., Ralston, K. J., Bates, R. C., and Burns, G. F. (2006) Biochem. Biophys. Res. Commun. 351, 51–56
17. Isenberg, J. S., Ridnour, L. A., Perruccio, E. M., Espey, M. G., Wink, D. A., and Roberts, D. D. (2005) Proc. Natl. Acad. Sci. U. S. A. 102, 13141–13146
18. Ignarro, L. J. (2005) Curr. Top. Med. Chem. 5, 595
19. Milkiewicz, M., Hudicka, O., Brown, M. D., and Silgram, H. (2005) Am. J. Physiol. Heart Circ. Physiol. 289, 336–343
20. Yu, J., deMunick, E. D., Zhuang, Z., Drinane, M., Kauser, K., Rubanyi, G. M., Qian, H. S., Murata, T., Escalante, B., and Sessa, W. C. (2005) Proc. Natl. Acad. Sci. U. S. A. 102, 10999–11004
21. Isenberg, J. S., Wink, D. A., and Roberts, D. D. (2006) Cardiovasc. Res. 71, 785–793
22. Isenberg, J. S., Ridnour, L. A., Dimitry, J., Frazier, W. A., Wink, D. A., and Roberts, D. D. (2006) J. Biol. Chem. 281, 26069–26080
50. Kanda, S., Mochizuki, Y., Nakamura, T., Miyata, Y., Matsuyama, T., and Kanetake, H. (2005) J. Cell Sci. 118, 961–970
51. van’t Hof, W., and Resh, M. D. (1997) J. Cell Biol. 136, 1023–1035
52. Koegl, M., Zlatkine, P., Ley, S. C., Courtneidge, S. A., and Magee, A. I. (1994) Biochem. J. 303, 749–753
53. Vaandrager, A. B., Ehlert, E. M., Jarchau, T., Lohmann, S. M., and de Jonge, H. R. (1996) J. Biol. Chem. 271, 7025–7029
54. Sessa, W. C., Barber, C. M., and Lynch, K. R. (1993) Circ. Res. 72, 921–924
55. Kou, R., Greif, D., and Michel, T. (2002) J. Biol. Chem. 277, 29669–29673
56. Perrino, B. A., and Martin, B. A. (2001) J. Biochem. (Tokyo) 129, 835–841
57. Krotova, K., Hu, H., Xia, S. L., Belayev, L., Patel, J. M., Block, E. R., and Zharikov, S. (2006) Br. J. Pharmacol. 148, 732–740
58. Sato, Y. (2004) Biol. Pharm. Bull. 27, 772–776
59. Kallander, L. S., Lu, Q., Chen, W., Tomaszek, T., Yang, G., Tew, D., Meek, T. D., Hofmann, G. A., Schulz-Pritchard, C. K., Smith, W. W., Janson, C. A., Ryan, M. D., Zhang, G. F., Johanson, K. O., Kirkpatrick, R. B., Ho, T. F., Fisher, P. W., Mattern, M. R., Johnson, R. K., Hansbury, M. J., Winkler, J. D., Ward, K. W., Veber, D. F., and Thompson, S. K. (2005) J. Med. Chem. 48, 5644–5647
50. Shintani, S., Li, C., Mihara, M., Klosek, S. K., Terakado, N., Hino, S., and Hamakawa, H. (2006) Oral Oncol. 42, 66–72
51. Murata, R., Nishimura, Y., and Hiraoka, M. (1997) Int. J. Radiat. Oncol. Biol. Phys. 37, 1107–1113
52. Rofstad, E. K., Galappathi, K., and Mathiesen, B. (2004) Int. J. Radiat. Oncol. Biol. Phys. 58, 493–499
53. Teicher, B. A., Holden, S. A., Ara, G., Sotomayor, E. A., Huang, Z. D., Chen, Y. N., and Brem, H. (1994) Int. J. Cancer 57, 920–925
54. Yap, R., Veliceasa, D., Emmenegger, U., Kerbel, R. S., McKay, L. M., Hennink, J., and Volpert, O. V. (2005) Clin. Cancer Res. 11, 6678–6685
55. French, K. J., Zhuang, Y., Schrecengost, R. S., Copper, J. E., Xia, Z., and Smith, C. D. (2004) J. Pharmacol. Exp. Ther. 309, 340–347
56. Selvakumar, P., Lakshmikuttyamma, A., Dimmock, J. R., and Sharma, R. K. (2006) Biochim. Biophys. Acta 1765, 148–154